Tarsus Pharmaceuticals Inc (TARS NASDAQ) stock market data APIs
$81.4701
0.03(0%)
as of December 5, 2025
Try our APIs with
free plan!
Tarsus Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Prev. Close
81.4701
Open
81.5031
High
81.5063
Low
81.4436
52 wk Range
38.51-83.47
Market Cap
3 471 M
Shares Outstanding
42 449 K
Revenue
366 M
EPS
-0.3
Beta
0.749
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tarsus Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tarsus Pharmaceuticals Inc data using free add-ons & libraries
Get Tarsus Pharmaceuticals Inc Fundamental Data
Tarsus Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 366 M
- EBITDA: -85 609 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.3645
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tarsus Pharmaceuticals Inc News
New
Can Tarsus Pharmaceuticals Stock Still Offer Value After Its 48% 2025 Rally?
If you are wondering whether Tarsus Pharmaceuticals is still worth buying after its big run, you are not alone. This article is going to walk through exactly what the market may be pricing in versus w...
Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You?
Key Points San Diego-based Tang Capital Management added 400,000 PTC Therapeutics shares in the third quarter. The value of the position increased by $38.3 million quarter over quarter. Tang Capital ...
Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In
Key Points San Diego-based Tang Capital Management bought nearly 1.2 million CELC shares. The move helped increase the fund's reported holdings in CELC by $56.8 million from quarter to quarter. It al...
Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet?
Key Points San Diego-based Tang Capital Management initiated new stake: up 12,400,000 shares, an estimated $40.8 million Change represents 1.6% of reportable assets under management Post-trade holdin...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
